ArticleJournal of the American Chemical Society2026
Site-Specific Hydrogen-Deuterium Exchange Mass Spectrometry for Deep Explorations of Dynamic Shifts in Protein-Drug Interactions.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogen-Deuterium eXchange Mass Spectrometry (HDX-MS) is a dynamics-sensitive structural method that has rapidly achieved widespread adoption in the biopharmaceuticals industry, owing to its ability to quickly identify binding sites and to provide a molecular mechanism of action for drug candidates. However, a central limitation of conventional HDX-MS is that it has substantially lower spatial resolution than other structural techniques, typically providing information averaged over "segments" of five amino acids or more. Here, we demonstrate a sensitive, broadly applicable method for single amino acid resolution, i.e., site-specific HDX-MS measurements. Using a set of five therapeutic candidates targeting the highly druggable cancer target WDR5, we explore the greatly enhanced analytical power that arises from site specificity, including binding mode characterization, affinity ranking, and the detection of features that are "silent" in conventional peptide-level HDX-MS experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.